Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.
Shares of Hims & Hers Health Inc. slid to a three-week low on Wednesday before recovering some losses, even as retail ...
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head ...
Eli Lilly (LLY) has announced it will make lower-priced, single-dose vials of its popular weight-loss treatment Zepound ...
Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.